Viewing Study NCT01564134


Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2025-12-30 @ 9:49 AM
Study NCT ID: NCT01564134
Status: COMPLETED
Last Update Posted: 2013-07-10
First Post: 2012-03-23
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Dose of Hepatitis B Vaccines in Non/Low-response Populations
Sponsor:
Organization:

Raw JSON

{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D017325', 'term': 'Hepatitis B Vaccines'}, {'id': 'C020361', 'term': 'gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide'}], 'ancestors': [{'id': 'D014761', 'term': 'Viral Hepatitis Vaccines'}, {'id': 'D014765', 'term': 'Viral Vaccines'}, {'id': 'D014612', 'term': 'Vaccines'}, {'id': 'D001688', 'term': 'Biological Products'}, {'id': 'D045424', 'term': 'Complex Mixtures'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 537}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-07', 'completionDateStruct': {'date': '2012-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-07-09', 'studyFirstSubmitDate': '2012-03-23', 'studyFirstSubmitQcDate': '2012-03-26', 'lastUpdatePostDateStruct': {'date': '2013-07-10', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-03-27', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2012-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Seroconversion rates of different doses of vaccines the levels of HBs-Ab after vaccination', 'timeFrame': 'day 30 after each vaccination', 'description': 'describe the levels of HBs-Ab after each vaccination and compare the percentages of adverse events in all groups'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['response vaccination'], 'conditions': ['Vaccination; Complications, Reaction, Serum']}, 'descriptionModule': {'briefSummary': 'An interventional study will be performed in subjects aged 1-65 years old to evaluate effects of different doses of hepatitis B vaccines in low or non-response population.', 'detailedDescription': 'A randomized clinical study will be conducted to evaluate effects of different doses of hepatitis B vaccines in low or non-response population in China. 650 low or non-response subjects after hepatitis B vaccination will be enrolled under the premise of informed consent. 200 subjects aged 1-17 years will be divided into 3 groups and 450 subjects aged 18-65years will be divided into 4 groups. Group 1/2/3 will receive 3 doses of vaccine on day 0,30 and 180, with 5ug/10ug/20ug HBs-Ag respectively. Group 4 will receive 1 dose of vaccine with 60ug HBs-Ag, low or nonresponse subjects of which will receive the second dose by an interval of at least 28 days. All vaccinations will be done by specific study personnel, who do not take part in the assessment of safety or immunogenicity. Adverse events will be recorded after vaccination and blood samples were collected at day 30 after each vaccination for antibody detection.\n\nThe clinical program approved by the ethics committee will be performed by the researchers independently. Inspectors designated by the sponsor will take meticulous on-site audits to ensure the safety specifications during the whole process of research.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '1 Year', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* aged 1-65 years old\n* male or non-pregnant female volunteers\n* provide written informed consents before joining the trial\n* clinically healthy as determined by: medical history inquiring and physical examination\n* negative for HBsAg,HBsAb,HBcAb,HBeAg,HBeAb within the past 1 year\n\nExclusion Criteria:\n\n* No history of hepatitis B vaccine\n* receipt of immunoglobulin within the past 1 month\n* allergic to any ingredient of vaccine\n* history of serious side effects, such as allergies, hives, breathing difficulties, angioedema or abdominal pain\n* severe acute and chronic diseases\n* autoimmune disease or immune deficiency\n* axillary temperature \\> 37.0 ℃ over the time of vaccination'}, 'identificationModule': {'nctId': 'NCT01564134', 'briefTitle': 'Dose of Hepatitis B Vaccines in Non/Low-response Populations', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Centers for Disease Control and Prevention, China'}, 'officialTitle': 'Effect of Dose of Hepatitis B Vaccines in Non/Low-response Populations', 'orgStudyIdInfo': {'id': 'BJCDCWJ201102'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'HepB 5ug', 'description': 'receive the vaccine with 5ug HBsAg', 'interventionNames': ['Biological: hepatitis B vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'HepB 10ug', 'description': 'receive the vaccine with 10ug HBsAg', 'interventionNames': ['Biological: hepatitis B vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'HepB 20ug', 'description': 'receive the vaccine with 20ug HBsAg', 'interventionNames': ['Biological: hepatitis B vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'HepB 60ug', 'description': 'receive the vaccine with 60ug HBsAg', 'interventionNames': ['Biological: hepatitis B vaccine']}], 'interventions': [{'name': 'hepatitis B vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['HepB 10ug: Hansenula Polymorpha Yeast', 'HepB 60ug: Saccharomyces cerevisiae'], 'description': 'hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg', 'armGroupLabels': ['HepB 10ug', 'HepB 20ug', 'HepB 5ug', 'HepB 60ug']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100011', 'city': 'Xicheng District', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Xicheng Centers For Disease Prevention & Control'}, {'zip': '024000', 'city': 'Chifeng', 'state': 'Inner Mongolia', 'country': 'China', 'facility': 'Chifeng Centers For Disease Prevention & Control', 'geoPoint': {'lat': 42.26833, 'lon': 118.96361}}], 'overallOfficials': [{'name': 'jiang wu, Bachelor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Beijing Centers for Disease Control and Prevention'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Wu Jiang', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'Beijing Municipal Science & Technology Commission', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Department of Immunization & Prevention', 'investigatorFullName': 'Wu Jiang', 'investigatorAffiliation': 'Centers for Disease Control and Prevention, China'}}}}